The next generation of cancer management.

摘要: As readers of Cancer Biology and Medicine well know, there has been a seismic shift in human molecular biology over the past few years, as momentous its own way discovery double-helical structure DNA by Watson Crick 60 years ago, elucidation genetic code shortly thereafter, advent recombinant gene cloning 1970s, introduction polymerase chain reaction mid-1980s. For first time history, we now have ready access to entire complement genes intergenic regions-all 6.6 billion nucleotides genome-of any individual, for either research or medical purposes. No longer limited our technology examining one individual sub-segment at traditional methods PCR Sanger sequencing, can produce, with astonishing accuracy precision, complete genome sequence within days reasonable cost. Nor are restricted particular cell type body site: obtain germline genomic from nucleated cells peripheral blood saliva, free fetal circulating mother's bloodstream, or-with singular relevance this special issue-the somatic cancer cells, revealing both their acquired "driver" secondary mutations that produce malignant phenotype serve potential targets "precision" "personalized" therapies.